This clinical trial focuses on studying Delayed Graft Function, a condition that can occur after kidney transplantation. The study tests a medication called ravulizumab (also known as ALXN1210), which is given through intravenous infusion. Some participants will receive the actual medication, while others will receive a placebo. The purpose is to determine if ravulizumab can reduce the severity of delayed graft function in adults who are at high risk of developing this condition after receiving a kidney from a deceased donor.

The study involves patients who have End-Stage Kidney Disease and require dialysis before their transplant. These patients will be receiving kidneys from deceased donors through either Donation after Circulatory Death or Donation after Brain Death. The treatment involves receiving either ravulizumab or placebo through an intravenous infusion. The medication or placebo will be given to patients who meet specific medical requirements determined by their healthcare providers.

The study will track how long patients need to remain on dialysis after their transplant and monitor their kidney function. Researchers will observe patients for 90 days after their transplant to evaluate how well the treatment works. During this time, they will measure how quickly patients can stop requiring dialysis and how well their new kidney functions.